• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SenesTech Inc. filed SEC Form 8-K: Leadership Update

    1/28/26 4:01:46 PM ET
    $SNES
    Agricultural Chemicals
    Industrials
    Get the next $SNES alert in real time by email
    snes-20260122
    false000168037800016803782026-01-222026-01-22

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF
    THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): January 22, 2026
    SenesTech, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3794120-2079805
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)(I.R.S. Employer
    Identification No.)
    13430 North Dysart Road, Suite 105
    Surprise, AZ
    85379
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (928) 779-4143
    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par valueSNES
    The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On January 22, 2026, Joel L. Fruendt, the President and Chief Executive Officer of SenesTech, Inc. (the “Company”), notified the Company that he will be retiring from the Company, including its Board of Directors (“Board”), effective upon the earlier of (i) June 30, 2026 and (ii) the date the Company appoints a successor Chief Executive Officer.

    In connection with his retirement, the Company entered into a separation agreement with Mr. Fruendt (the “Separation Agreement”). Pursuant to the Separation Agreement, and subject to the Company’s receipt of an effective release and waiver of claims from him, Mr. Fruendt will be entitled to receive the following severance compensation and other benefits: (1) cash severance benefits in the form of continuation of his base salary through December 15, 2026 (subject to applicable withholdings); (2) payment or reimbursement of premiums for health insurance coverage until December 31, 2026; and (3) acceleration of the vesting of the stock options held by Mr. Fruendt.

    On January 26, 2026, the Board appointed Jamie Bechtel as Interim Executive Chair of the Company. As compensation, Ms. Bechtel will receive $247,500 per year for her service as Interim Executive Chair of the Company, which is in addition to any other compensation she may receive as a member of the Board and any committees of the Board.

    The foregoing description of the material terms of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which the Company intends to file with the Securities and Exchange Commission as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.



    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: January 28, 2026
    SENESTECH, INC.
    By:
    Thomas C. Chesterman
    Executive Vice President, Chief Financial Officer, Treasurer and Secretary

    Get the next $SNES alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNES
    SEC Filings

    View All

    Amendment: SenesTech Inc. filed SEC Form 8-K: Leadership Update

    8-K/A - SenesTech, Inc. (0001680378) (Filer)

    1/28/26 5:26:33 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Inc. filed SEC Form 8-K: Leadership Update

    8-K - SenesTech, Inc. (0001680378) (Filer)

    1/28/26 4:01:46 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form SCHEDULE 13G filed by SenesTech Inc.

    SCHEDULE 13G - SenesTech, Inc. (0001680378) (Subject)

    11/24/25 4:01:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Expands International Reach with the Addition of the Belize Raptor Center as an Official Distributor of Evolve® Rat Birth Control

    SURPRISE, Ariz., Nov. 11, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the pioneer in fertility control for managing animal pest populations, proudly announces the addition of Sarah Mann and the Belize Raptor Center as the newest international distributor of Evolve® Rat Birth Control. Through the leadership of Sarah Mann with the support of the Pesticides Control Board of Belize, Evolve Rat received approval for import and distribution in Belize, a country whose biodiversity is being threatened by the alarming increase of unregulated rodenticides and the severe ecologic

    11/11/25 9:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

    77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights Revenues increased by 43% to $690,000, a record for the Company, from $482,000 in Q3 2024.Evolve® Rodent Birth Control product sales

    11/10/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leach Jacob Steven sold $168 worth of shares (62 units at $2.71), closing all direct ownership in the company (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    11/19/25 7:48:43 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Director Szot Matthew K sold $3 worth of shares (1 units at $2.75), closing all direct ownership in the company (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    11/17/25 3:00:12 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    New insider Edell Michael claimed no ownership of stock in the company (SEC Form 3)

    3 - SenesTech, Inc. (0001680378) (Issuer)

    11/4/25 6:25:44 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Names Nicole Williams as Chief Revenue Officer

    PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye

    2/16/23 9:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces Appointment of Vector and Pest Control Industry Veteran Joel Fruendt as Chief Executive Officer

    PHOENIX, Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period. This leadership transition is part of SenesTech's ongoing strategic plan to drive the commercialization of ContraPest, its flagship product.

    11/14/22 9:10:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by SenesTech Inc.

    SC 13G - SenesTech, Inc. (0001680378) (Subject)

    11/12/24 4:30:48 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Financials

    Live finance-specific insights

    View All

    SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

    77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights Revenues increased by 43% to $690,000, a record for the Company, from $482,000 in Q3 2024.Evolve® Rodent Birth Control product sales

    11/10/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern time PHOENIX, Nov. 3, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for pest management, will report third quarter 2025 financial results for the period ended September 30, 2025, after the market close on Monday, November 10, 2025. The Company has scheduled a conference call that same day, Monday, November 10, 2025, at 5:00 p.m. Eastern time, to review the results. Third Quarter 2025 Conference Call Details Date and Time: Monday, Novem

    11/3/25 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins

    94% Revenue Growth in Evolve™ Rodent Birth Control Products Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., Aug. 7, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the second quarter ended June 30, 2025. Q2 2025 Highlights Revenues increased 36% to $625,000, a record for the Company, from $459,000 in Q2 2024.Evolve Rodent Birth Control products sales grew 94%

    8/7/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials